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Abstract
The goal of this study was to determine the frequency of HLA class II antigen expression in colorectal carcinoma
(CRC) tumors, its association with the clinical course of the disease, and the underlying mechanism(s). Two tissue
microarrays constructed with 220 and 778 CRC tumors were stained with HLA-DR, DQ, and DP antigen–specific
monoclonal antibody LGII-612.14, using the immunoperoxidase staining technique. The immunohistochemical
staining results were correlated with the clinical course of the disease. The functional role of HLA class II antigens
expressed on CRC cells was analyzed by investigating their in vitro interactions with immune cells. HLA class II
antigens were expressed in about 25% of the 220 and 21% of the 778 tumors analyzed with an overall frequency
of 23%. HLA class II antigens were detected in 19% of colorectal adenomas. Importantly, the percentage of
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stained cells and the staining intensity were significantly lower than those detected in CRC tumors. However, HLA
class II antigen staining was weakly detected only in 5.4% of 37 normal mucosa tissues. HLA class II antigen
expression was associated with a favorable clinical course of the disease. In vitro stimulation with interferon
gamma (IFNγ) induced HLA class II antigen expression on two of the four CRC cell lines tested. HLA class II antigen
expression on CRC cells triggered interleukin-1β (IL-1β) production by resting monocytes. HLA class II antigen
expression in CRC tumors is a favorable prognostic marker. This association may reflect stimulation of IL-1β production
by monocytes.
Neoplasia (2014) 16, 31–42
Introduction
According to genetic profiles, colorectal carcinoma (CRC) tumors are
classified in two groups. About 75% of patients have CRC tumors
of sporadic origin, with no clear evidence of having inherited the
disease. In contrast, about 25% of patients with CRC tumors are
likely to have a hereditary contribution. The cause of an inherited
CRC tumor risk involves defects in the DNA mismatched repair
(MMR) system leading to an increased possibility of colorectal cells
to acquire mutations [1]. MMR deficiency condition seems to
be associated with high density of lymphocyte infiltration, reduced
invasiveness, and improved survival [2].
Besides being expressed on antigen presenting cells, B lympho-
cytes, and activated T lymphocytes, HLA class II antigens are also
expressed in a variety of malignant tumors of different embryological
origin. The frequency of expression reaches 74.5% in medullary
breast carcinoma, 17.7% in ductal breast carcinoma [3], 100% in
renal cell carcinoma [4], and 60% in primary melanomas [5]. In
some malignancies such as melanomas [6] and osteogenic sarcoma
[7], HLA class II antigen expression is associated with poor prognosis,
while it is associated with favorable prognosis in cervical carcinoma [8]
and in squamous cell carcinoma of the larynx [9]. Limited information
is available about HLA class II antigen expression in CRC tumors and
its clinical significance. To the best of our knowledge, a total of only
two large studies involving more than 300 patients have been ac-
complished so far. The first study included 357 patients with micro-
satellite stable CRC tumors [10]; the second study involved 1016 CRC
patients with rectal carcinoma [11]. The average frequency of HLA
class II antigen expression has been found to be 38% with ranges from
21% to 55% [12]. Conflicting information is available about the clini-
cal significance of HLA class II antigen expression in CRC tumors.
HLA class II antigen expression in CRC tumors has been reported to
be associated with favorable prognosis by Lovig et al., Matsushita et al.,
and Morita et al. [10,13–15] and in a population of patients with rectal
carcinoma by de Bruin et al. [11] but also with irrelevant prognosis
because HLA class II antigen expression in CRC cells was not asso-
ciated with the clinical course of the disease by Moller et al., Mulder
et al., Diederichsen et al., and Momburg et al. [16–19]. The reason(s)
for these conflicting results is (are) not known.
In human, presence of inflammatory infiltrate, in CRC tumors,
has been associated with favorable prognosis [2,20]. HLA class II
antigens play a pivotal role in stimulating an inflammatory response
against pathogen and tumor antigens. They are not expressed in
normal colonic epithelium but could be detected in CRC cells.
Furthermore, HLA class II antigen expression in colonic epithelial
and CRC cells is inducible on stimulation with interferon gamma
(IFNγ) [21]. These data suggest that HLA class II antigen expression
in the CRC tumors may result from the activity of pro-inflammatory
cytokines and may be associated with immunostimulation.
Information about HLA class II antigen expression in CRC tumors
and its clinical significance may contribute to our understanding of
the role of these molecules in the interactions of CRC tumors with
the host’s immune system and to the design of strategies to modulate
these interactions. Therefore, in the present study, we have determined
the frequency of HLA class II antigen expression in about 1000 CRC
tumors, using two tissue microarrays (TMAs) independently con-
structed at two medical centers. Furthermore, we have analyzed the
association of HLA class II antigen expression in CRC tumors with
their histopathologic characteristics and the clinical characteristics of
the disease. Lastly, we have investigated the potential role of pro-
inflammatory cytokines in the functional properties of HLA class II
antigens expressed by CRC cells.
Materials and Methods
Colorectal Specimens and TMAs
Retrospective materials obtained from formalin-fixed paraffin-
embedded biopsies of surgically removed CRC tumors were separately
collected and stored in the Institutes of Pathology at the University
of Athens (Athens, Greece) and at the biobank of the Institute of
Pathology at the University of Basel (Basel, Switzerland). The use
of these tissue specimens and data for analysis was approved by the
Regional Ethics Committee.
The Athens study comprised 220 nonconsecutive CRC tissue
resections. In addition, we included 42 colorectal adenomas and
37 normal colonic mucosa tissues obtained from surgical resections
of tumor-free areas adjacent to CRC tumors. The Basel study com-
prised 1420 unselected nonconsecutive CRC tissue resections [20].
The TMAs were constructed as described elsewhere [22]. How-
ever, only 778 CRC tumor punches, also obtained from surgical
resection with tumor-free margins, contained ≥80% of malignant
cells and, therefore, were suitable for evaluation, while the remain-
ing spots were unavailable because of missing representative CRC
tissues (Table 1).
Briefly, formalin-fixed paraffin-embedded tissue blocks of CRC resec-
tions were obtained. Tissue cylinders (0.6-mm diameter) were punched
from morphologically representative tissue areas of each donor tissue
block in a paraffin block recipient by a semiautomated tissue arrayer.
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Each punch was made from the center of the tumor such that each
TMA spot consisted of at least 50% tumor cells.
Antibodies
LGII-612.14 monoclonal antibody (mAb) recognizes monomorphic
epitope expression in the β chain of HLA-DR, DQ, and DP anti-
gens. The antibody was prepared and characterized as described [23].
Antibody specificity was validated by immunoprecipitation, ELISA,
and binding assay. Peroxidase-labeled secondary antibody was pur-
chased from Dako (Glostrup, Denmark). Fluorescein isothiocyanate–
conjugated goat anti-mouse Ig and anti–HLA-DR antibodies were
purchased from BD Biosciences (San Jose, CA). Phycoerythrin-
conjugated anti–HLA-DR, DQ, DP antibodies were purchased from
Abcam (Cambridge, United Kingdom).
Cell Lines and Peripheral Blood Mononuclear Cells
COLO205, HCT116, HT29, and SW480 cell lines were cultured
in Dulbecco’s modified Eagle’s medium supplemented with heat-
inactivated FBS. The identity of the indicated cell lines was monitored
by HLA class I and II antigen expression and in vitro growth pattern.
Peripheral blood mononuclear cells (PBMCs) were isolated from
healthy donors’ buffy coats of the Policlinico “Tor Vergata” blood
bank, using the Ficoll-Hypaque density gradient separation method
[24]. PBMCs were cultured in RPMI 1640 medium (Life Technologies
Europe, Milan, Italy) supplemented with heat-inactivated FBS, gluta-
mine (2 mM), streptomycin (100 U/ml), and penicillin (100 U/ml);
this medium is referred to as the complete medium.
Immunohistochemistry
TMAs were stained with a two-step procedure using mAb LGII-
612.14 as a primary antibody and a peroxidase-labeled rabbit anti-
mouse IgG antibody as a secondary antibody. Following dewaxing
and rehydration of the TMA slides, in distilled water, endogenous
peroxidase activity was blocked with a 0.5%H2O2 solution. Colorectal
tissue sections were then incubated with mAb LGII-612.14 for 30min-
utes at room temperature. Following three washes with phosphate-
buffered saline, tissue sections were incubated with peroxidase-labeled
secondary antibody for 30 minutes at room temperature. For antigen
visualization, colorectal tissues were soaked for 30 minutes at room
temperature in 3-amino-9-ethylcarbazole (Dako) supplemented with
substrate-chromogen and counterstained with Gill’s hematoxylin
(Dako). CRC punches were evaluated for HLA class II antigen
expression by counting the total number of positive cells detected in
each tumor punch. HLA class II antigen–positive CRC and inflam-
matory cells were clearly identified by morphologic evaluation. Results
were validated by at least three independent investigators achieving an
optimal concordance rate of 90%.
Quantitative Reverse Transcription–Polymerase Chain
Reaction of Gene Expression in Colorectal Tissues
Following the Basel Internal Review Board (IRB) approval (63/07),
freshly obtained specimens from surgically excised CRC, not included
in the tumor associated macrophage (TAM) collection, and autologous
normal colorectal mucosa samples at a distance from the tumor were
submerged in RNAlater (Qiagen, Venlo, The Netherlands) and stored
overnight at 4°C. Samples were then frozen at −20°C for long-term
storage. Total cellular RNA was extracted using RNeasy Mini Kit
(Qiagen) allowing routine purification of high-quality RNA. RNA was
then subjected to reverse transcription (RT) using M-MLV reverse
transcriptase (Invitrogen, Carlsbad, CA). Quantitative RT–polymerase
chain reaction (qRT-PCR) was performed using the TaqMan uni-
versal PCR master mix (Applied Biosystems, Foster City, CA) and the
following primers and probes:
for IFNγ [25], forward: AGCTCTGCATCGTTTTGGGTT,
reverse: GTTCCATTATCCGCTACATCTGAA and probe:
FAM-TCTTGGCTGTTACTGCCAGGACCCA-TAMRA;
interleukin-1β (IL-1β): primers and probes were purchased as a
kit (ref. Hs99999029_m1) from Applied Biosystems and used
according to the manufacturer’s instructions;
for IL-6 [26], forward: CAGCCCTGAGAAAGGAGACATG,
reverse: GGTTCAGGTTGTTTTCTGCCA and probe: FAM-
AGTAACATGTGTGAAAGCAGCAAA-GAGGCAC-TAMRA;
for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [26],
forward: ATGGGGAAGGTGAAGGTCG, reverse: TAAAAG-
CAGCCCTGGTGACC and probe: FAM-CGCCCAATACG-
ACCAAATCCGTT-GAC-TAMRA.
Gene expression was quantified as already described [27]. Normaliza-
tion of gene expression was done on the GAPDH housekeeping gene.
Flow Cytometry
CRC cells were incubated on ice, for 30 minutes, in the presence
of 1 μg per million cells of the HLA class II antigen–specific mAb
Table 1. Clinicopathologic Features of 778 Patients with Valuable CRC Tumor Punches of the
Basel Study.
Features N Percentage
CRC tumors 778 100
Gender
Females 395 51
Males 383 49
HLA class II tumor antigens
Positive 164 21
Negative 614 79
pN stage
N0 376 48
N1 199 26
N2 153 20
Unknown 50 6
Invasive margins
Negative 228 29
Positive 509 66
Unknown 41 5
Vascular invasion
Negative 536 69
Positive 202 26
Unknown 40 5
Grade
1 16 2
2 647 83
3 75 10
Unknown 40 5
T stage
1 32 4
2 113 15
3 485 62
4 111 14
Unknown 37 5
MMR status
Deficient 115 15
Proficient 640 82
Unknown 23 3
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LGII-612.14. Following two washes, cell surface–bound antibodies
were detected using fluorescein-conjugated anti-mouse IgG anti-
bodies. Cells then were analyzed using a two-laser BD FACSCalibur
equipped with a Cell Quest software package (Beckton-Dickinson,
San Jose, CA).
Magnetic Sorting of Peripheral Blood Monocytes
Freshly isolated PBMCs (50-70 × 106) were washed twice in modi-
fied MACS buffer (phosphate-buffered saline supplemented with
0.5% bovine albumin). Then, 50 to 70 μl (1 μl per 1 million of
PBMCs) of anti-CD14 magnetic beads (Miltenyi Biotec, Bergisch
Gladbach, Germany) was added to the PBMC pellet. Following a
30-minute incubation on ice, cells were washed twice in modified
MACS buffer. Cells were resuspended in 1 ml of modified MACS
buffer and passed through a 0.40-μm cell strainer (BD Falcon, San
Jose, CA), in a magnetic column. CD14+ cells retained in the column
were eluted by a strong mechanical pressure. Following two washes,
monocytes were resuspended at the concentration of 1 × 106/ml, in
complete medium, for functional experiments.
Cytokine Array
The amount of cytokines in the supernatant harvested from cul-
tures of COLO205 and PBMCs was assessed, using a duplicate of
42 human cytokine array system (RayBiotech Inc, Norcross, GA),
which detects the antibody-cytokine sandwich by chemiluminescence.
For cytokine blocking experiments, before PBMCs or monocytes
were mixed with COLO205 cells, FcγRs of PBMCs or monocytes
were blocked using mouse IgG (6-10 μg/ml) or FcγR blocking solu-
tion (Miltenyi Biotec). HLA class II antigen blockade was accom-
plished by incubating IFNγ (10 ng/ml)–treated COLO205 cells
with 3 μg of LGII-612.14 mAb for 30 minutes on ice in 100 μl of
complete medium.
Enzyme-Linked Immunosorbent Assay
IL-1β and IL-6 levels were measured in the supernatants harvested
from the cultures using commercially available IL-1β (BD Biosciences)
and IL-6 (R&D Systems, Minneapolis, MN) ELISA kits with a sen-
sitivity of 0.80 and 0.70 pg/ml, respectively. Supernatants harvested
from cultures of COLO205 and PBMCs were added, in triplicates,
to wells previously coated with anti–IL-1β or anti–IL-6 capture
antibodies. Wells were covered with plate sealers, incubated for
2 hours at room temperature, and washed five times with 300 to
400 μl of wash buffer. Following the last wash, plates were blotted
on absorbent paper to remove the remaining buffer. Then, 100 μl of
biotin-conjugated anti–IL-1β antibody or 200 μl of HRP-conjugated
anti–IL-6 antibody was added to each well for 2 hours at room tem-
perature. Following extensive washing, substrates were added, and
plates were incubated for 30 minutes at room temperature in the
dark. Reactions were stopped by adding 50 μl of stop solution to each
well. The absorbance was read at 450 nm within 30 minutes.
Statistical Analysis
HLA class II antigen–positive CRC cells were analyzed, in each
CRC tumor punch, by counting a maximum number of 100 positive
cells. The threshold for this marker was calculated by means of
receiver operating characteristic curve analysis in the testing collective
of Athens. Punches containing ≤15 and >15 HLA class II antigen–
positive CRC cells were scored negative and positive, respectively.
The calculated threshold was tested in the collective of Basel. Survival
time differences were evaluated using the log-rank test in univariate
analysis. Multivariate hazard Cox regression analysis was performed
by adjusting for CRC standard prognostic factors including pT, pN,
tumor grade, vascular invasion, age, and metastasis. Hazard ratios and
95% confidence intervals were used to calculate the validity of the
prognostic effect.
Correlation analysis among biologic markers was assessed using
the Spearman rank correlation coefficient.
Statistical analyses were performed using SPlus software (version
6.1; Insightful Corporation, Seattle, WA) and Statistical Analysis
System software (SAS Institute, Cary, NC).
Results
Association of HLA Class II Antigen Expression with
Disease Progression in CRC Tumors
HLA class II antigens were found to be expressed by CRC cells in
about 23% of the tumors tested. Representative staining patterns
are shown in Figure 1, which indicates that the majority of CRC
cells were stained by mAb LGII-612.14 in the tumors expressing
HLA class II antigens (Figure 1A). In contrast, HLA class II antigens
were detected in about 95% of inflammatory infiltrating cells of the
CRC tumors analyzed. Representative examples are shown in Figure 1,
B and C . HLA class II antigens were not detected in cells of normal
colorectal mucosa but were found to be expressed by immune cells
in the interstitial tissues (Figure 1D).
We next investigated whether HLA class II antigen expression was
associated with malignant transformation of colorectal cells. To this
end, we compared HLA class II antigen expression in 37 normal
colorectal mucosa samples, in 42 colorectal adenomas, and 220 CRC
tumors. The frequency of HLA class II antigen expression increased
with disease progression because it was about 5% in the normal mucosa
samples tested, about 19% in the colorectal adenoma samples tested,
and about 25% in the CRC tumors tested. Furthermore, in CRC
tumors, the percentage of stained malignant cells and their staining
intensity were significantly higher than those found in colorectal
adenomas (P < .013) and in normal colorectal mucosa (P < .0001;
Table 2). The difference, in HLA class II antigen expression, between
normal colorectal mucosa and colorectal adenoma was also significant
(P = .01) corroborating the conclusion that in colorectal mucosa HLA
class II antigen expression is associated with disease progression.
Association of HLA Class II Antigen Expression in
CRC Cells with Patients’ Prolonged Survival
To assess the clinical significance of HLA class II antigen expression
by CRC cells, we correlated it with the histopathologic characteristics
of the lesions and with the clinical characteristics of the patients. For
this analysis, patients were divided into the following two groups:
those who contained >15 malignant cells, per TMA, stained by mAb
LGII-612.14 in their tumor punches and those who contained <15.
The presence of ≤15 CRC cells stained by mAb LGII-612.14
in tumor punches was significantly associated with lymph node
involvement (P < .0001), presence of metastasis (P < .0021), and
lymphatic invasion (P ≤ .008). Table W1 shows a detailed des-
cription of the association of HLA class II antigen expression with
tumor stage in the Athens study. There was a significant association
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between low HLA class II antigen–positive CRC cell counts and high
tumor stage (P < .0001). Similar results were obtained in the larger
collective of the Basel study (data not shown). However, there was
no association with the histologic characteristics of the tumors, as
well as their grade and location. Furthermore, the survival of patients
with ≤15 CRC cells stained by mAb LGII-612.14 in their tumor
punches was significantly shorter than that of patients with >15
malignant cells stained by mAb LGII-612.14 in their tumor punches.
To determine whether HLA class II antigen expression in CRC
cells was an independent prognostic marker, we performed a multi-
variate survival analysis of HLA class II antigen expression in CRC
cells and pT, pN, and metastasis. Table W2 shows that HLA class II
antigen expression in CRC cells was an independent favorable
prognostic factor.
Because the American Society of Clinical Oncology (ASCO) guide-
lines for the identification of new biologic tumor markers recommend
data validation at least by an independent study, we assessed the im-
pact of HLA class II antigen expression on the overall survival (OS) of
patients with CRC in an additional group of patients of the Basel
study. Of 778 patients with CRC whose tumors were used for immuno-
histochemical analysis, 742 patients were also available for an OS estima-
tion. Univariate analysis confirmed that patients with (N = 153) CRC
tumors having >15 malignant cells, per tumor punch, stained by mAb
LGII-612.14 had a significantly (0.007) longer OS time than pa-
tients (N = 589) with CRC tumors having ≤15 CRC cells, per tumor
punch, stained by mAb LGII-612.14.
Furthermore, we investigated in 730 patients with CRC of the
Basel study the impact of the HLA class II antigen–positive inflam-
matory cells in the CRC tumors on the OS of patients with CRC.
Figure 2C shows that patients (N = 688) with CRC tumors having
>6 HLA class II antigen–positive inflammatory cells, per tumor
punch, had a longer OS time than patients (N = 42) with CRC
tumors having ≤6 HLA class II antigen–positive inflammatory cells
per tumor punch. However, the difference did not reach the level of
statistical significance (P = .09).
We then assessed the relationship between HLA class II anti-
gen expression and the inflammatory infiltrate of the CRC tumors.
Table 2. Athens Study: HLA Class II Antigens Are Preferentially Expressed in CRC Cells of
Colorectal Tissues.
Histopathology Normal Mucosa Adenoma CRC
N 37 42 220
HLA class II+ colorectal tissues 2 8 55
HLA class II− colorectal tissues 35 34 165
Min. number of HLA class II− cells 0 0 0
Max. number of HLA class II+ cells 20 100 100
Mean+ cells 1.4 11.7 21.4
Statistical analysis P < .05 P < .0001
The expression of HLA class II antigens in colorectal mucosae was evaluated by immunohisto-
chemistry as described in the Materials and Methods section.
N , sample size; Min. and Max., minimal and maximal absolute cell numbers of HLA class II
antigen–positive cells detected in the colorectal tissues.
Figure 1. Expression of HLA class II antigens in the CRC tumors. Post-resection colorectal tissues were stained with the anti–HLA
class II antigen LGII-612.14 mAb as indicated in the Materials and Methods section. Positive cells are stained in brown. The upper panel
shows representative examples of powerful CRC cell positivity (A) and negativity (B) for HLA class II antigens. B also shows a certain
degree of HLA class II antigen–positive inflammatory cells into the interstitial tissues of the CRC tumor. C documents the presence
of HLA class II antigen–negative CRC cells and the presence of HLA class II antigen–positive inflammatory cells. D shows a normal
colorectal tissue. Normal colorectal glands were clearly HLA class II antigen–negative, while HLA class II antigen–positive cells were
restricted to the interstitial tissues.
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Table W3 shows that CRC tumors with HLA class II antigen–
positive CRC cells correlated with the presence of CD16+ myeloid
and T cell antigens. Conversely, there was no correlation with natural
killer (NK)–NK-T and myeloid markers. Tumors rich in HLA class
II antigen–positive inflammatory cells maintained a weak but signif-
icant correlation with the majority of immune markers indicated
in Table W3. These data suggest that there may be a correlation
between HLA class II antigen expression and CD16 myeloid and T cell
infiltration [20,28,29].
IFNγ, IL-1β, and IL-6 Expression in Freshly Removed
CRC Tumors
Because HLA class II antigens are pivotal players of the immune
response and their expression can be induced by pro-inflammatory cyto-
kines including IFN-γ, we explored the expression of pro-inflammatory
cytokines by qRT-PCR in CRC tumors and normal colorectal mucosae.
Among 10 CRC tumors available, 10 were evaluated for IFNγ and
IL-1β gene expression and 9 for IL-6 gene expression. CRC tumors
contained IFNγ (P = .004), IL-1β (P = .001), and IL-6 (P = .001)
gene expression levels significantly higher than those assessed in normal
colonic mucosae (Figure 3).
COLO205 Cells and PBMCs Trigger IL-1β and
IL-6 Inflammatory Cytokine Production
Because inflammatory cytokines are capable of polarizing macro-
phage toward M1 phenotype, we investigated whether HLA class II
antigen–positive CRC cells in the presence of allogeneic PBMCs could
contribute to develop an inflammatory microenvironment in vitro.
Following a 48-hour incubation with IFNγ at 37°C, two of four
CRC cell lines including COLO205 and HT29 cells expressed HLA
class II antigens (Figure 4). However, IFNγ did not induce CD80,
CD86, and CD18 expression (data not shown). These results suggest
that HLA class II antigens are heterogeneously expressed among
CRC cell lines.
Figure 5A shows that resting PBMCs and COLO205 cells without
or with HLA class II antigen expression produced traces of transforming
Figure 2. HLA class II antigen expression is associated with im-
proved OS in CRC of the Athens and Basel studies. (A) Survival
probability according to the Athens study: The red line shows OS
probability of CRC patients with HLA class II antigen–positive CRC
cells; the blue line shows OS of CRC patients with HLA class II
antigen–negative CRC cells. (B) Survival probability according to
the Basel study: The red line shows OS probability of CRC patients
with HLA class II antigen–positive CRC cells; the blue line showsOS
probability of CRC patients with HLA class II antigen–negative CRC
cells. (C) Survival probability according to the level of infiltration of
HLA class II antigen–positive or –negative inflammatory cells. The
red line shows OS probability of CRC patients with their CRC tumors
infiltrated by HLA class II antigen–positive immune cells; the blue
line shows OS probability of CRC patients with their CRC tumors
noninfiltrated by HLA class II antigen–positive immune cells. Statis-
tical differences between groups are indicated. The definition of
HLA class II antigen–positive or –negative tumors is described in
the Materials and Methods section.
Figure 3. Gene expression of the pro-inflammatory cytokines IL-1β,
IFNγ, and IL-6 in freshly resected CRC tumors and normal colorectal
mucosa. CRC tumors and normal colorectal mucosae (CM) were ob-
tained during surgery and placed in Falcon tubes. Following mecha-
nical separation and DNA digestion, total RNA was isolated from
CRC and colorectal tissues and subjected to RT. Then, cDNA was
analyzed by qRT-PCR for IL-1β, IFNγ, and IL-6 gene expression as de-
scribed in the Materials and Methods section. Data are expressed as
a ratio toGAPDH housekeeping gene as indicated; solid circles repre-
sent normal colorectal mucosa; solid squares represent CRC tumors.
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growth factor–β1 (TGF-β1) but did not secrete IL-4 and IL-13.
However, supernatants harvested from cultures of COLO205 cells
and PBMCs showed changes in M2 cytokine content since there was
an increase in the level of IL-13. Furthermore, we noted a reduction
of IL-13 production when PBMCs were cultured in the presence of
HLA class II antigen–positive COLO205 cells. These results suggest
that HLA class II antigen–positive COLO205 cells failed to induce
the production of TGF-β1, IL-4, and IL-13 cytokines.
We next investigated whether HLA class II antigen–positive
COLO205 cells could affect the production of IL-1β and IL-6.
Following a 48-hour incubation of PBMCs with or without HLA
class II antigen–positive or –negative COLO205 cells, supernatants
harvested from a culture of PBMCs and HLA class II antigen–positive
COLO205 cells showed high contents in IL-1β. In contrast, a lower
amount of IL-1β was detected in the supernatants harvested from a
culture of PBMCs and HLA class II antigen–negative COLO205 cells
(Figure 5B, upper panel). Resting PBMCs and HLA class II antigen–
negative or –positive COLO205 cells did not produce IL-6. Con-
versely, supernatants obtained from a culture of PBMCs and HLA
class II antigen–negative COLO205 cells contained levels of IL-6
lower than those detected in the supernatants harvested from a cul-
ture of PBMCs and HLA class II antigen–positive COLO205 cells
(Figure 5C , upper panel). These results suggest that the production of
IL-1β and IL-6 in the supernatants of PBMCs and COLO205 was
associated with HLA class II antigen expression on COLO205 cells.
To assess the impact of HLA class II antigens on IL-1β and IL-6
production, PBMCs were cultured in the presence of HLA class II
antigen–positive COLO205 cells coated with or without anti–HLA
class II antigen mAb. Figure 5B, lower panel, shows that IL-1β produc-
tion in the cell cultures composed of HLA class II antigen–positive
COLO205 cells and PBMCs was inhibited by the HLA class II anti-
gen–specific mAb LGII-612.14, whereas IL-6 production was not
(Figure 5C , lower panel ). These results strongly suggest that HLA
class II antigens played a role in the secretion of IL-1β. Similar results
were obtained when IL-1β and IL-6 cytokine production was assessed
using an ELISA (Figure 5D).
IL-1β Production Involved Monocytes
Because IL-1β is typically produced by monocyte/macrophage, we
assessed whether co-cultures of monocytes and HLA class II antigen–
positive COLO205 generated IL-1β. Supernatants harvested from
a culture of monocytes and HLA class II antigen–positive COLO205
cells obtained from three healthy donors (Figure 6A) showed the high-
est content of IL-1β (Figure 6B). Conversely, supernatants harvested
from a cell culture consisting of monocytes cultured in the absence of
COLO205 cells, or PBMCs, depleted of monocytes, with or without
HLA class II antigen–positive COLO205 cells did not produce IL-1β,
suggesting that IL-1β production requires the presence of monocytes
and HLA class II antigen–positive COLO205 cells.
To identify whether monocytes or HLA class II antigen–positive
COLO205 cells secreted IL-1β, we incubated monocytes with HLA
class II antigen–negative or –positive COLO205 cells. Subsequently,
monocytes were magnetically separated from COLO205 cells,
and both cells were placed in a single culture condition. Following a
48-hour incubation, the supernatants harvested from resting mono-
cytes or COLO205 cells negative and positive for HLA class II antigen
expression as well as COLO205, previously stimulated with monocytes,
did not show significant production of IL-1β. Conversely, monocytes
previously stimulated with HLA class II antigen–positive COLO205
cells produced most of the IL-1β detected in the supernatants of the
different culture conditions. As expected, lipopolysaccharides (LPS)
and IFNγ stimulation of monocytes, which were used as positive con-
trols, induced IL-1β production (Figure 6C ). These results suggest
that HLA class II antigen–positive COLO205 cells specifically triggered
IL-1β by monocytes.
Discussion
In this study, we investigated HLA class II antigen expression in a large
collection of about 1000 CRC tumors recruited in two independent
European institutions. Immunohistochemical analysis of the CRC
tumor showed an overall frequency of HLA class II antigen expres-
sion of 23% ranging between 21% of the Basel study and 25% for
the Athens study. In contrast, 95% of CRC TMA punches analyzed
Figure 4. IFNγ induced HLA class II antigen expression in COLO205 and HT29 CRC cell lines. CRC cell lines COLO205, HT29, SW480,
and HCT116 were cultured in the presence or absence of IFNγ (10 ng/ml). Following a 48-hour stimulation, cells were indirectly stained
with the anti–HLA class II antigen mAb LGII-612.14. Cell surface–bound LGII-612.14 was detected using a fluorescein isothiocyanate
goat anti-mouse F(ab)2. The blue lines show LGII612.14 staining, while the red lines show the fluorescence intensity given by the
secondary antibody used as a negative control.
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had HLA class II antigen–positive inflammatory cells. Furthermore,
when CRC tumors were classified as positive, in most of the cases,
the frequency of the CRC positive cells was high, and the intensity
of the staining was particularly strong. Our results are in agreement
with the study of de Bruin et al. who find an expression frequency
of about 21% but are conflicting with Lovig et al. who found a fre-
quency of HLA class II antigen expression of 51% [10]. A possible
explanation for this difference may involve the choice of the investiga-
tors to consider different cutoff scores to define positive or negative
CRC tumors. Our choice to consider the threshold of 15 positive cells
was based on information obtained from receiver operating character-
istic curve analysis in the collective of Athens and validated in the
independent collective of Basel. Alternatively, it could be also possible
to speculate that there were different levels of cytokine production in
the CRC tumors used in these studies. Finally, HLA class II antigen
expression disparity may reflect different molecular profiles of the
CRC tumors included in these studies. However, we tend to exclude
this hypothesis because, although the Athens study only included
MMR-proficient CRC tumors, while the Basel study included 83%
and 17% of MMR-proficient and MMR-deficient CRC tumors,
Figure 5. HLA class II antigen expression on CRC cells regulated IL-1β production in the cell cultures composed of COLO205 cells and
PBMCs. COLO205 CRC cells were cultured in the presence or absence of IFNγ (10 ng/ml) for 48 hours in complete medium. HLA class II
antigen expression on COLO205 cells was confirmed by flow cytometry. After extensive washes, COLO205 cells and freshly isolated
PBMCs were co-cultured, in the absence of IFNγ, for 48 hours at 1:4 ratios, respectively, according to the indicated experimental con-
ditions. Following a 48-hour incubation, supernatants were evaluated in duplicates for the presence of TGF-1β, IL-4, IL-13 (A), IL-1β
(B, upper panel), and IL-6 (C, upper panel) cytokines using a cytokine array. HLA class II antigen–positive COLO205 cells were cultured
in the presence or absence of blocking anti–HLA class II antigen mAbs (6 μg/ml) for 30 minutes at 4°C. Then, cells were washed and
cultured in the presence of freshly isolated PBMCs whose FcγRs were previously blocked using mouse IgG. Following a 48-hour
incubation, supernatants were harvested and analyzed in duplicates for IL-1β (B, lower panel) and IL-6 (C, lower panel) contents. Tripli-
cates of 100 μl of supernatants obtained after 30 hours of culture condition indicated in the x-axis were analyzed for IL-1β (D, upper
panel) and IL-6 (D, lower panel) protein content by ELISA. In all situations, where blocking conditions were performed, COLO205 cells
were pre-coated with the anti–HLA class II antigen mAb LGII-612.14, while PBMC FcγRs were blocked using a commercially available
blocking buffer (Miltenyi, Bologna, Italy). Cytokine protein spots were analyzed by photo densitometry and expressed as OD relative
units calculated as follows: cytokine spotsOD/standard control spotsOD × 100. Abbreviations: II, HLA class II antigen–positive; a-II ag, anti–HLA
class II antigen mAb LGII-612.14; mono, monocytes.
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respectively, no significant differences in HLA class II antigen expres-
sion were observed between the groups. In agreement with the studies
of Lovig et al. and de Bruin et al., we found that HLA class II antigen
expression in the CRC tumor cells was a favorable prognostic factor.
However, these results are not in agreement with other studies that
suggest that HLA class II antigen expression is at least an indifferent
prognostic factor without being associated with a favorable clinical
course of the disease [16–18]. Explanation(s) for these conflicting re-
sults is (are) not known. The existence of such a conflicting situation
prompted us the idea that HLA class II antigen expression in the
CRC tumor could be significant but not sufficient to generate a tumor
microenvironment predisposing to a favorable clinical course of the
disease. Then, other factors such as local cytokine production and or
type and function of inflammatory immune cells may be involved in
such a process.
The expression of HLA class II antigens could be a result of the
activation of an inflammatory response mediated by immune cells
infiltrating the tumor microenvironment [2,20,30–36]. CRC tumors
for a variety of reasons including their microenvironment, rich in
bacterial flora, undergo active infiltration of inflammatory cells com-
posed of T lymphocytes and TAMs but limited in NK cells [32].
Thus, the expression of HLA class II antigens is likely to be due
to IFNγ producing immune cells during the inflammation process.
Indeed, we have found that IFNγ gene expression was upregulated
in the CRC tumor microenvironment. Furthermore, in agreement
with published results [37], IFNγ triggered HLA class II antigen
expression on the cell surface of 50% of CRC cell lines used, includ-
ing COLO205 and HT29 cells. Because CRC tumor microenviron-
ment is hardly infiltrated by NK cells and rich in T lymphocytes, it
is likely to predict that CD4-positive lymphocytes are responsible
for the local production of IFNγ.
HLA class II antigen expression in CRC cells, in the presence of
IFNγ, is controlled by the methylation of class II transactivator–
isoform-PIV (PIV) and is inhibited by somatic mutation of the
RFX5 gene [21]. Although, we have not tested our CRC cell lines
for FRX5 mutation, we also found that HLA class II antigen expression
Figure 6. HLA class II antigen–dependent IL-1β production was produced by monocytes. PBMCs were isolated from three healthy
donors. (A) monocytes were obtained using anti–CD14-conjugated magnetic beads by positive selection. CD14-depleted PBMCs were
obtained harvesting unbound cells flowing through the magnetic columns. After cell sorting, monocytes were stained in the presence of
an allophycocyanin (APC)-conjugated anti-CD33 mAb. The purity of myeloid cells was higher than 95%. (B) Following monocyte isolation,
1 × 106/ml CD14+ or CD14− cells were plated onto 96-well plates in the presence or absence of 0.25 × 106 HLA class II antigen–positive
COLO205 cells. After a 30-hour incubation, supernatants were harvested and analyzed in triplicates for IL-1β content by ELISA. (C) CD14
magnetic bead–labeled monocytes were cultured in the presence or absence of HLA class II antigen–positive or –negative COLO205 cells
for 5 hours. Then, cells were vigorously resuspended and passed through magnetic columns. Unbound COLO205 cells were harvested
and seeded in a 96-well plate, while magnetically labeled monocytes retained in the columns were detached by a mechanical pressure.
Monocytes were harvested and cultured according to the indicated experimental conditions in 96-well plates. Following a 30-hour incu-
bation, supernatants harvested from cultures of COLO205 cells or monocytes were assessed for IL-1β content. Supernatants harvested
from cultures of resting HLA class II antigen–positive or –negative cells were also used as negative controls. Abbreviations: II, HLA class II
antigen–positive; mono, monocytes.
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requires the presence of class II transactivator–PIV (data not shown).
These results suggest possible mechanisms controlling HLA class II an-
tigen expression in CRC cells on stimulation with IFNγ.
There is an increased consensus supporting the positive effect of
a strong inflammatory response, in the CRC tumors, on the OS of
patients with CRC [38]. Interestingly, the favorable contribution
of TAM infiltration to the clinical course of the patients with CRC
makes this disease a compelling exception among solid malignancies
investigated so far [20,29,39–42]. Thus, HLA class II antigen
expression in the CRC tumors could play a role in counteracting
CRC progression. This situation raises questions about mechanisms
by which HLA class II antigen expression in CRC cells protects the
host against the tumor.
In this context, we suggest that HLA class II antigen expression in
CRC may cause an immunologic antitumor response [20,29,31].
HLA class II antigen expression on CRC cells could activate CD4+
T cells by presenting tumor-associated antigens (TAAs). Indeed, a
certain number of TAA have been described in CRC [43–48]. How-
ever, HLA class II antigen expression is not sufficient to develop a
successful CD4+ T cell stimulation because it requires the expression
of co-stimulatory molecules on tumor cells [49].
Accordingly, in the allogeneic setting, IFNγ induced HLA class II
antigen expression but failed to generate B7, B7.1, and CD18 ex-
pression on COLO205 cells. As a consequence, we failed to produce
a CD4+ T cell proliferation (data not shown). However, HLA class II
antigen expression on COLO205 cells induced the production of
pro-inflammatory cytokines including IL-1β and IL-6 by monocytes
but failed to generate anti-inflammatory cytokines including TGF-β,
IL-13, and IL-4.
IL-1β is a pro-inflammatory cytokine, and the expression of the
IL-1β receptor is required for an efficient activation of dendritic
cells (DC). Furthermore, IL-1β induces macrophage recruitment
and macrophage auto-stimulation [50] shaping a pro-inflammatory
microenvironment with a potential antitumor activity [20,29,33].
IL-1β and IL-6 molecules are pro-inflammatory cytokines mainly
produced by granulocyte/monocytes [51,52]. IL-6 molecule promotes
the transition from acute to chronic phase of inflammation reducing
granulocyte trafficking and increasing monocyte recruitment at the
damaged tissues [52]. Thus, a pro-inflammatory infiltrate is likely to
have a positive clinicopathologic effect on the clinical course of human
CRC tumors. However, these results are not in agreement with mouse
models of CRC because inflammation has been found to be involved
in the pathogenesis of colitis-associated cancer. According to these
studies, in the tumor microenvironments, IL-6 secreted by bone
marrow–derived myeloid cells activates signal transducer and activator
of transcription 3 (STAT3) signaling pathways leading to the concen-
tration of β-catenin into the nuclei favoring tumor progression. In
addition, IL-1β can also induce IL-6 production promoting colitis-
associated cancer progression [53].
Thus, in human and mouse, inflammation is differently linked to
CRC tumors. There is evidence that inflammation is connected to
cancer intrinsic and extrinsic pathways. The intrinsic pathway is
activated by genetic modifications leading to inflammation and can-
cer. The extrinsic pathway involves CRC tumors growing in a tumor
microenvironment with a preexistence of inflammatory condition
such as ulcerative colitis and Chron’s disease [54]. Most of the
CRC tumors evaluated rose in mice with inflammatory bowel diseases,
while the majority of our patients had no underlying inflammatory
conditions. These differences may explain the conflicting results ob-
tained in human and mouse studies. Then, inflammation developing
in CRC tumors derived from genetic alteration may have protective
activity. In contrast, inflammation of CRC tumors derived from
colorectal mucosa chronically affected by inflammatory diseases may
generate a qualitative different inflammation that may promote cancer
progression. However, ulcerative colitis and Chron’s disease are often
associated with immune dysregulation. The idea that inflammation
could be good and bad in CRC tumors is also reinforced by Klintrup
et al. [38]. These investigators found that inflammatory cell infiltra-
tion at the invasive margin, in CRC, was a favorable prognostic factor,
while Richards et al. showed that systemic inflammation was a poor
prognostic marker in patients with CRC [55].
In human, certain HLA-DR genotype alleles have been associated
with ulcerative colitis [56]. It is tempting to speculate that aberrant
expression of HLA class II antigens may differentially affect the patho-
genesis of malignant and autoimmune diseases having a protective role
in CRC but a detrimental one in autoimmune diseases [57]. However,
aberrant expression of HLA class II antigens worsened the clinical out-
come of thyroiditis, type I diabetes, and biliary cirrhosis [58–60].
According to our study, HLA class II antigen–positive cells induced
IL-1β production in peripheral blood monocytes. We and others
have shown that CRC tumor is rich in TAMs. Phenotypic analysis
of freshly infiltrating cells indicates two types of TAMs: The first is
CD16 positive, while the second is CD16 negative. CD16-positive
TAMs are CD11c high and are associated with survival. Thus, It is
possible to speculate that these cells could be a target of IL-1β in the
context of CRC tumors perhaps favoring DC differentiation.
Considering that HLA class II antigen expression may be induced
in the presence of IFNγ, it could be possible to use this cytokine as
a platform for developing personalized immunotherapeutic studies.
To avoid the adverse effect and the nonspecific stimulation of IFNγ
on the immune system, we may think to deliver IFNγ into the
CRC tumors using anti–TAA-IFNγ fusion proteins. However, Trinh
et al. have demonstrated that is possible to deliver IFNβ to human
lymphoma using an anti–CD10–IL-1β fusion protein [61].
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Table W1. Association of HLA Class II Antigen Expression and Tumor-Node-Metastasis Stage.
Stage HLA Class II Antigens N (%) P Value
Low High
I 23 (16.6) 22 (31.0) <.0001
II 29 (20.9) 27 (38.0)
III 66 (47.5) 21 (29.6)
IV 21 (15.1) 1 (1.4)
Total N 139 71
CRC tumor punches were screened for HLA class II antigen expression. CRC tumors were
considered HLA class II positive low when the total count of HLA class II–positive CRC cells
was ≤15 and high when it was >15.
Table W2. Multivariate Survival Time Analysis of HLA Class II Antigen Expression with pT, pN,
and Metastasis.
Feature P Value Hazard Ratio (95% Confidence Interval)
HLA class II .0075 0.43 (0.24-0.8)
pT stage .2746 1.55 (0.71-3.42)
pN stage .0028 2.44 (1.36-4.37)
Metastasis <.0001 3.53 (2.0-6.2)
Table W3. Spearman Rank Correlation Coefficients between HLA Class II Antigen and Biologic Antigen Expression in the CRC Tumors.
Feature* CRC Class II Ags Infiltrate Class II Ags CD16 CD56 CD57 CD68 CD3 CD4 Peri-T CD8 Granzyme Intra-T
CRC HLA class II Ags 1 – 0.20 0.04 0.07 0.1 0.19 0.05 0.29 0.25
Infiltrate HLA class II Ags 0.18 1 0.29 0.16* 0.20 0.24 0.26 0.11 0.16 0.15
Bolded correlation coefficient (r) numbers are significant and have P values < .001.
All comparisons were performed with more than 420 paired values.
All correlation are positive and weak though significant.
*P = .003.
